- Home
- AL vs ACAD Comparison
AL vs ACAD Comparison
Compare AL & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AL
- ACAD
- Stock Information
- Founded
- AL 2010
- ACAD 1993
- Country
- AL United States
- ACAD United States
- Employees
- AL N/A
- ACAD N/A
- Industry
- AL Diversified Commercial Services
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- AL Consumer Discretionary
- ACAD Health Care
- Exchange
- AL Nasdaq
- ACAD Nasdaq
- Market Cap
- AL 4.7B
- ACAD 3.8B
- IPO Year
- AL 2011
- ACAD 2004
- Fundamental
- Price
- AL $57.52
- ACAD $22.54
- Analyst Decision
- AL Buy
- ACAD Buy
- Analyst Count
- AL 5
- ACAD 18
- Target Price
- AL $61.40
- ACAD $27.71
- AVG Volume (30 Days)
- AL 654.8K
- ACAD 2.1M
- Earning Date
- AL 08-04-2025
- ACAD 08-05-2025
- Dividend Yield
- AL 1.53%
- ACAD N/A
- EPS Growth
- AL 15.59
- ACAD N/A
- EPS
- AL 5.72
- ACAD 1.37
- Revenue
- AL $2,808,629,000.00
- ACAD $996,283,000.00
- Revenue This Year
- AL $10.00
- ACAD $13.28
- Revenue Next Year
- AL $7.18
- ACAD $11.06
- P/E Ratio
- AL $10.07
- ACAD $16.50
- Revenue Growth
- AL 3.56
- ACAD 22.42
- 52 Week Low
- AL $38.25
- ACAD $13.40
- 52 Week High
- AL $60.41
- ACAD $25.23
- Technical
- Relative Strength Index (RSI)
- AL 48.28
- ACAD 59.56
- Support Level
- AL $57.31
- ACAD $20.87
- Resistance Level
- AL $58.94
- ACAD $23.12
- Average True Range (ATR)
- AL 1.09
- ACAD 0.68
- MACD
- AL -0.23
- ACAD 0.04
- Stochastic Oscillator
- AL 8.83
- ACAD 75.32
About AL Air Lease Corporation
Air Lease Corp is an aircraft leasing company based in the United States. It is engaged in purchasing commercial jet aircrafts directly from aircraft manufacturers and leasing those aircraft to airlines throughout the world to generate attractive returns on equity. The company also sells aircraft from its fleet to third parties, including other leasing companies, financial services companies, airlines, and other investors, and offers fleet management services to investors and owners of aircraft portfolios for a management fee. Geographically, it derives a majority of its revenue from the Asia-Pacific region and the rest from Europe, Middle East and Africa, Central America, South America, Mexico, the United States, and Canada.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.